drugset / Trial / NCT00884390
Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study will be investigating safety in patients who switch to ReFacto AF from ReFacto and other Factor VIII products.
Timeline
- Start
- 2009-05
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moroctocog alfa | Protein / enzyme biologic | — | — |